ABC Transporters at the Blood–Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Drug delivery into the brain is regulated by the blood–brain interfaces. The blood–brain barrier (BBB), the blood–cerebrospinal fluid barrier (BCSFB), and the blood–arachnoid barrier (BAB) regulate the exchange of substances between the blood and brain parenchyma. These selective barriers present a high impermeability to most substances, with the selective transport of nutrients and transporters preventing the entry and accumulation of possibly toxic molecules, comprising many therapeutic drugs. Transporters of the ATP-binding cassette (ABC) superfamily have an important role in drug delivery, because they extrude a broad molecular diversity of xenobiotics, including several anticancer drugs, preventing their entry into the brain. Gliomas are the most common primary tumors diagnosed in adults, which are often characterized by a poor prognosis, notably in the case of high-grade gliomas. Therapeutic treatments frequently fail due to the difficulty of delivering drugs through the brain barriers, adding to diverse mechanisms developed by the cancer, including the overexpression or expression de novo of ABC transporters in tumoral cells and/or in the endothelial cells forming the blood–brain tumor barrier (BBTB). Many models have been developed to study the phenotype, molecular characteristics, and function of the blood–brain interfaces as well as to evaluate drug permeability into the brain. These include in vitro, in vivo, and in silico models, which together can help us to better understand their implication in drug resistance and to develop new therapeutics or delivery strategies to improve the treatment of pathologies of the central nervous system (CNS). In this review, we present the principal characteristics of the blood–brain interfaces; then, we focus on the ABC transporters present on them and their implication in drug delivery; next, we present some of the most important models used for the study of drug transport; finally, we summarize the implication of ABC transporters in glioma and the BBTB in drug resistance and the strategies to improve the delivery of CNS anticancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“conserved “cassette-like” domain that catalyzes the ATP hydrolysis providing the energy needed for the transport of substances against a concentration gradient [39] (Figure 2A).”
BackgroundMembrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Zhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., Vogel, H., Steinberg, G. K., Edwards, M. S. B., Li, G., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.013 · Cited by 2,295 · cited 3×
“According to the RNA-Seq brain transcriptome, Abcg2 in mouse [85] and ABCG2 in humans [65] is expressed mostly in endothelial cells, but low transcript levels could”
A gene expression atlas of the central nervous system based on bacterial artificial chromosomes
Gong, S., Zheng, C., Doughty, M. L., Losos, K., Didkovsky, N., Schambra, U. B., Nowak, N. J., Joyner, A., Leblanc, G., Hatten, M. E., et al. (2003) · Nature · doi:10.1038/nature02033 · Cited by 2,108
Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS
Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W., & Gygi, S. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0832254100 · Cited by 1,733
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Helms, H. C., Abbott, N. J., Burek, M., Cecchelli, R., Couraud, P.-O., Deli, M. A., Förster, C., Galla, H. J., Romero, I. A., Shusta, E. V., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16630991 · Cited by 843
Glioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812 · cited 5×
“Most tumors express ABCB1/P-gp in high levels [346], including schwannomas, meningiomas, low-grade gliomas (astrocytomas, pilocytic astrocytomas), and high-grade gliomas (GBMs, anaplastic astrocytomas, and anaplastic oligodendrogliomas) [66,346].”
BackgroundInfluentialDerivation of blood-brain barrier endothelial cells from human pluripotent stem cells
Lippmann, E. S., Azarin, S. M., Kay, J. E., Nessler, R. A., Wilson, H. K., Al-Ahmad, A., Palecek, S. P., & Shusta, E. V. (2012) · Nature Biotechnology · doi:10.1038/nbt.2247 · Cited by 800 · cited 4×
“After differentiation and isolation, the hPSC-derived brain endothelial cells monolayers present key BBB characteristics, including tight junctions and functional ABC transporters [158,159,172].”
BackgroundInfluentialThe hCMEC/D3 cell line as a model of the human blood brain barrier
Weksler, B., Romero, I. A., & Couraud, P.-O. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-16 · Cited by 753 · cited 1×
“The human immortalized endothelial cell line hCMEC/D3 [153,154] is widely used for the study of drug transport [163–166] because it has been thoroughly characterized and it expresses ABC and SLC transporters, as well as tight junctions [167–169], despite the fact that the tightness of its monolayer is lower than in in…”
MethodSarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746 · cited 1×
“It is often assumed that the BBTB is completely disrupted; thus, its barrier function is often neglected during GBM drug design [329,330], but there are increasing clinical evidences showing that all the GBM present tumor zones with intact BBB, hindering drug permeability into the tumor (reviewed in [330]).”
BackgroundAdvances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662 · cited 7×
“Most tumors express ABCB1/P-gp in high levels [346], including schwannomas, meningiomas, low-grade gliomas (astrocytomas, pilocytic astrocytomas), and high-grade gliomas (GBMs, anaplastic astrocytomas, and anaplastic oligodendrogliomas) [66,346].”
BackgroundInfluentialHow artificial intelligence is changing drug discovery
Fleming, N. (2018) · Nature · doi:10.1038/d41586-018-05267-x · Cited by 546
CSF, blood-brain barrier, and brain drug delivery
Pardridge, W. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1171315 · Cited by 508 · cited 1×
“Diverse strategies have been devised to improve drug delivery into the brain for the treatment of CNS diseases (reviewed in [18,41,366]) and in the particular case of brain tumors (reviewed in [14,367–369]).”
BackgroundLippmann, E. S., Al-Ahmad, A., Azarin, S. M., Palecek, S. P., & Shusta, E. V. (2014) · Scientific Reports · doi:10.1038/srep04160 · Cited by 508
Ghersi-Egea, J.-F., Strazielle, N., Catala, M., Silva-Vargas, V., Doetsch, F., & Engelhardt, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1807-1 · Cited by 436 · cited 13×
“This last function is performed mainly by transporters from the ATP-binding cassette (ABC) superfamily [3], and to a lesser extent, the solute carrier (SLC) superfamily exchangers [1], both of which have a key role in the absorption, distribution, metabolism, and excretion (ADME) of drugs.”
BackgroundInfluentialShawahna, R., Uchida, Y., Declèves, X., Ohtsuki, S., Yousif, S., Dauchy, S., Jacob, A., Chassoux, F., Daumas-Duport, C., Couraud, P.-O., et al. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200129p · Cited by 372 · cited 18×
“(C) Primary or cell lines of brain endothelial cells (EC) can be cultured (a) directly in wells to study drug absorption or (b) in transwells for permeability assays; (c to f) cocultures with other cells from the NVU can improve the BBB phenotype, including the tight junctions (black rhombus ♦); (g and h).”
BackgroundMethodInfluentialSelf-citationMass spectrometry imaging for drug distribution studies
Prideaux, B., & Stoeckli, M. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.07.028 · Cited by 279
Hoshi, Y., Uchida, Y., Tachikawa, M., Inoue, T., Ohtsuki, S., & Terasaki, T. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23575 · Cited by 254 · cited 5×
“mass-spectrometry coupled to liquid chromatography (LC-MS/MS) has revealed different levels of ABC transporters in isolated brain microvessels in rodents and primates [93].”
BackgroundMethodInfluentialA Novel Transwell Blood Brain Barrier Model Using Primary Human Cells
Stone, N. L., England, T. J., & O’Sullivan, S. E. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00230 · Cited by 251 · cited 5×
“In addition, some enterprises commercialize human primary cells of astrocytes, pericytes, BMVEC, and neurons that can be used for in vitro modeling of the BBB, which recently allowed the evaluation and comparison of complex cocultures containing combinations of these components of the NVU [182].”
BackgroundInfluentialWeller, R. O., Sharp, M. M., Christodoulides, M., Carare, R. O., & Møllgård, K. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1809-z · Cited by 222 · cited 2×
“The meninges are composed of three layers; starting with the outermost pachymeninx composed of a fibrous sheet of dura mater; then, the two innermost layers form the leptomeninges, including the arachnoid mater followed by the pia mater lining the brain, both enclosing CSF in the subarachnoid space [32] (Figure 1D).”
BackgroundMetabolic enzymes as oncogenes or tumor suppressors
Thompson, C. B. (2009) · New England Journal of Medicine · doi:10.1056/nejme0810213 · Cited by 213
Duan, J., Mansour, H. M., Zhang, Y., Deng, X., Chen, Y., Wang, J., Pan, Y., & Zhao, J. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.01.020 · Cited by 194 · cited 1×
“For instance, doxorubicin-curcumin nanoparticles have proven an increased accumulation in vitro [434] and in vivo in cancer preclinical models, which has been accompanied by a reduced cardiotoxicity [435].”
BackgroundSumi, N., Nishioku, T., Takata, F., Matsumoto, J., Watanabe, T., Shuto, H., Yamauchi, A., Dohgu, S., & Kataoka, Y. (2010) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9446-7 · Cited by 179 · cited 1×
“An improvement in the expression of tight junctions and BBB phenotypes have been observed when brain endothelial cells are cocultured in two-chamber systems with astrocytes [144,149,176–178], pericytes [179], neurons [180], or microglia [181]; furthermore, a synergic effect is seen when several cell types of the NVU a…”
BackgroundTranslation in astrocyte distal processes sets molecular heterogeneity at the gliovascular interface
Boulay, A. C., Saubaméa, B., Adam, N., Chasseigneaux, S., Mazaré, N., Gilbert, A., Bahin, M., Bastianelli, L., Blugeon, C., Perrin, S., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.5 · Cited by 179
Self-citationSaunders, N. R., Habgood, M. D., Møllgård, K., & Dziegielewska, K. M. (2016) · F1000Research · doi:10.12688/f1000research.7378.1 · Cited by 143 · cited 5×
“They form a tight monolayer lacking fenestration due to especially tight junctions (TJs) between the cells, restricting the paracellular movement of small polar substances and macromolecules [1,18].”
BackgroundInfluentialDrug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier
Yasuda, K., Cline, C., Vogel, P., Onciu, M., Fatima, S., Sorrentino, B. P., Thirumaran, R. K., Ekins, S., Urade, Y., Fujimori, K., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050344 · Cited by 128
Vu, K., Weksler, B., Romero, I., Couraud, P.-O., & Gelli, A. (2009) · Eukaryotic Cell · doi:10.1128/ec.00240-09 · Cited by 124
Grifno, G. N., Farrell, A. M., Linville, R. M., Arevalo, D., Kim, J. H., Gu, L., & Searson, P. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-50193-1 · Cited by 112
Matsumoto, K., Chiba, Y., Fujihara, R., Kubo, H., Sakamoto, H., & Ueno, M. (2015) · Histochemistry and Cell Biology · doi:10.1007/s00418-015-1366-7 · Cited by 46
Cited by
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
Teleanu, R. I., Preda, M. D., Niculescu, A.-G., Vladâcenco, O., Radu, C. I., Grumezescu, A. M., & Teleanu, D. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050987 · Cited by 200
Lipid Transport and Metabolism at the Blood-Brain Interface: Implications in Health and Disease
Pifferi, F., Laurent, B., & Plourde, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.645646 · Cited by 148
Co-Culture Models: Key Players in In Vitro Neurotoxicity, Neurodegeneration and BBB Modeling Studies
Monteiro, A. R., Barbosa, D. J., Remião, F., & Silva, R. (2024) · Biomedicines · doi:10.3390/biomedicines12030626 · Cited by 27
Metadata
- Authors
- Gomez-Zepeda, D., Taghi, M., Scherrmann, J.-M., Decleves, X., & Menet, M.-C.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2019-12-23
- Volume
- 12
- Issue
- 1
- Pages
- 20
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W2995199382
- Cited by
- 124
- References
- 34
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.